We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Collection Tubes Compared for Glucose Values

By LabMedica International staff writers
Posted on 04 Apr 2013
Blood glucose concentrations in samples collected with barrier serum tubes and plasma tubes with anticoagulants have been compared. More...


Blood specimens for plasma glucose analysis have been collected in tubes which contain sodium fluoride (NaF), to prevent coagulation and glycolysis, and an inhibitor potassium oxalate (KOx) and compared with samples collected in barrier serum tubes.

Scientists at the University of Ottawa (ON, Canada) collected serum and plasma samples were under field conditions from a single draw of 3,692 individuals. Collection was performed using a 4.0 mL plasma NaF/KOx tube and a 7.5 mL serum separator tubes (SST) tube; both are from the BD Vacutainer range (Becton–Dickinson; Franklin Lakes, NJ, USA).

Plasma and serum specimens were analyzed on a Vitros 5.1 FS analyzer (Ortho-Clinical Diagnostics Inc. Raritan, NJ, USA) using the VITROS GLUSlide method, which has a multilayered, analytical element coated on a polyester support. Paired specimens from both SST and NaF/KOx draws from each respondent were analyzed using the same lot of reagent, eliminating any lot-to-lot variability in the results.

A total of 495 paired samples were used in the final comparison. There was a high rate of 86.2% hemolysis in the NaF/KOx tubes, while hemolysis was infrequently observed with only 2% the SST tubes. Comparing only blood draws where no hemolysis was observed in both tubes showed no effect of tube type on serum/plasma glucose concentrations. This was also observed when data was restricted to cases when only SST samples were not hemolyzed. The mean glucose concentrations measured in plasma was 4.85 ± 1.25 mmol/L and in serum was 4.84 ± 1.24 mmol/L, which was not significantly different.

The authors concluded that both collection tubes can be used under survey collection and processing conditions to measure glucose with this assay system with no difference in reported results. The elimination of NaF/KOx tubes would provide process and operational advantages and a significant cost saving measure for national population-based surveys. The study was published in the March 2013 issue of the journal Clinical Biochemistry.

Related Links:
University of Ottawa
Becton–Dickinson
Ortho-Clinical Diagnostics Inc.



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.